Health-related quality of life associated with warfarin and direct oral anticoagulants in venous thromboembolism

• Published in: Thrombosis research 2022-08, Vol.216, p.97-102
• Main Authors: Fang, Margaret C, Go, Alan S, Prasad, Priya A, Zhou, Hui X, Parks, Anna L, Fan, Dongjie, Portugal, Cecilia, Sung, Sue Hee, Reynolds, Kristi
• Format: Article
• Language: English
• Subjects: Administration, Oral; Adult; Anticoagulants - therapeutic use; Female; Hemorrhage - drug therapy; Humans; Male; Quality of Life; Retrospective Studies; Venous Thromboembolism - drug therapy; Warfarin - adverse effects
• ISSN: 0049-3848; 1879-2472
• DOI: 10.1016/j.thromres.2022.06.008

Venous thromboembolism (VTE) is commonly treated with oral anticoagulants, including warfarin or direct oral anticoagulants (DOACs). Although DOACs are associated with favorable treatment satisfaction, few studies have assessed whether quality of life differs between DOAC and warfarin users. We invited adults enrolled in two California-based integrated health care delivery systems and with a history of VTE between January 1, 2015 and June 30, 2018 to complete a survey on their experience with anticoagulants. Health-related quality of life (QOL) was assessed using the RAND 36-item Short Form Health Survey (SF-36), which measures QOL in 2 general component scores (physical and mental). We used multivariable linear regression to compare mean QOL component scores between DOAC-users and warfarin-users, adjusting for patient and clinical characteristics. Overall, 2230 patients (43.1 % women and 31.8 % >75 years of age) taking anticoagulants answered at least 1 question on the SF-36, 975 taking DOACs and 1255 taking warfarin. After adjustment for patient-level factors, there were no significant differences in either physical component scores (39.2 v 38.3, p = 0.24) or mental component scores (48.5 v 49.0, p = 0.42) between DOAC and warfarin users. Health-related QOL did not significantly differ between DOAC and warfarin users with a history of VTE.